XML 85 R69.htm IDEA: XBRL DOCUMENT v3.22.4

Commitments and Contingencies (Details)											1 Months Ended	9 Months Ended	12 Months Ended	18 Months Ended
	Apr. 19, 2022 case	Mar. 11, 2022 stockholder	Mar. 07, 2022 stockholder	Dec. 24, 2021 USD ($) case	Dec. 16, 2021 USD ($)	Sep. 11, 2020	Mar. 05, 2020 case	Oct. 02, 2019	Mar. 24, 2015 patent	Feb. 11, 2015 USD ($) patent	Feb. 28, 2022 case	Sep. 30, 2022 case	Dec. 31, 2021 case	Apr. 30, 2017 patent	Apr. 30, 2017 lawsuit
Commitments and Contingencies
Number of lawsuits filed												6
Claims settled				27
Xtampza ER Litigation
Commitments and Contingencies
Number of patents listed in FDA Orange Book | patent										11
Number of Orange Book patents asserted to have been infringed | $										5
Stay period before FDA can issue a final approval unless it is terminated									30 months	30 months
Number of patents allegedly infringed									3					2	2
PTAB duration for issuing decision								1 year
Statutory period of proceedings						18 months
Xtampza ER Litigation | Maximum
Commitments and Contingencies
PTAB extended duration for issuing decision								6 months
Opioid Litigation
Commitments and Contingencies
Number of lawsuits dismissed	8												13
Litigation settlement, amount awarded to other party | $				$ 2,750,000
Claims settled				27
Multi-District Litigation (MDL)
Commitments and Contingencies
Number of patents allegedly infringed													21
Number of lawsuits dismissed												3
Claims settled				8
State court
Commitments and Contingencies
Claims settled				19
Opioid-Related Request and Subpoenas
Commitments and Contingencies
Agreed to pay attorney general | $					$ 185,000
Reimbursement of investigation cost of the attorney general | $					$ 65,000
BDSI Acquisition Litigation
Commitments and Contingencies
Number of additional cases filed							2				2
Number of demand letters received from purported stockholders | stockholder		4	3

X

- Definition

Initial duration for issuing its decision by PTAB.

+ References

No definition available.

+ Details

Name:	coll_DurationForDecisionIssue
Namespace Prefix:	coll_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Extended period for issuing its decision by PTAB.

+ References

No definition available.

+ Details

Name:	coll_ExtendedDurationForDecisionIssue
Namespace Prefix:	coll_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of additional cases filed.

+ References

No definition available.

+ Details

Name:	coll_LossContingencyNumberOfAdditionalCasesFiled
Namespace Prefix:	coll_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of demand letters received from purported stockholders.

+ References

No definition available.

+ Details

Name:	coll_LossContingencyNumberOfDemandLettersReceivedFromPurportedStockholders
Namespace Prefix:	coll_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of another entity's Orange Book patents that the entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	coll_LossContingencyOrangeBookPatentsAllegedlyInfringedNumber
Namespace Prefix:	coll_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The reimbursement of investigation cost incurred by the Attorney General.

+ References

No definition available.

+ Details

Name:	coll_LossContingencyReimbursementOfInvestigationCost
Namespace Prefix:	coll_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the stay period before the Federal Drug Administration (FDA) can issue final approval unless the stay is terminated.

+ References

No definition available.

+ Details

Name:	coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected
Namespace Prefix:	coll_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of patents listed in FDA Orange Book

+ References

No definition available.

+ Details

Name:	coll_NumberOfPatentsListedInFdaOrangeBook
Namespace Prefix:	coll_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Statutory period of proceedings.

+ References

No definition available.

+ Details

Name:	coll_StatutoryPeriodOfProceedings
Namespace Prefix:	coll_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount awarded to other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of claims dismissed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of claims settled.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyClaimsSettledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyLossInPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=coll_OpioidLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=coll_MultiDistrictLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=coll_OpioidLitigationStateCourtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=coll_OpioidRelatedRequestAndSubpoenasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=coll_BdsiAcquisitionLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: